ALNA News and Press, Allena Pharmaceuticals Inc. From 03/16/20

Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.47 beats by $0.06 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Streamlined URIROX-2 Design Potentially Reduces Target Length and Cost of Trial -- -- Regulatory Engagement on Registrational Path for Reloxaliase in High-Risk Enteric Hyperoxaluria (EH) Patients with Chronic Kidney Disease (CKD) Expected in 2Q 2020 -- -- Investigational New D...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “This morning, ALNA announced proposed changes to URIROX-2, including reduction of overall EH patients (200 vs. 400) and adding an interi...

NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

AIM ImmunoTech (NYSEMKT: AIM ) +20%  on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus. More news on: AIM ImmunoTech Inc., TransEnterix, Inc., Shopify Inc., Stocks on the move, , Read more ...

Thinly traded nano cap Allena Pharmaceuticals (NASDAQ: ALNA ) is up  11%  premarket on average volume on the heels of its announcement that the FDA has signed off, at least in principle, on a streamlined design for its second Phase 3 study evaluating reloxaliase for the potential...

-- Reducing Target Enrollment to 200 Subjects -- --  Conducting Earlier Interim Analysis, Expected in Q3 2021 -- -- Company to Host Conference Call at 8:30 a.m. ET Today  -- NEWTON, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a lat...

– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) – – Plan to Re-Engage with U.S. Food and Drug Administration (FDA) to Evaluate Opportunities to Streamline URIROX-2, Second Pivotal Phase 3 Trial of Reloxaliase in EH&...

NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...